{"id":695953,"date":"2024-04-22T17:52:01","date_gmt":"2024-04-22T17:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=695953"},"modified":"2024-04-22T17:52:01","modified_gmt":"2024-04-22T17:52:01","slug":"bipolar-disorder-pipeline-assessment-2024-indepth-insights-into-the-emerging-drugs-latest-fda-approvals-clinical-trials-therapies-key-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bipolar-disorder-pipeline-assessment-2024-indepth-insights-into-the-emerging-drugs-latest-fda-approvals-clinical-trials-therapies-key-companies_695953.html","title":{"rendered":"Bipolar Disorder Pipeline Assessment, 2024 | In-depth Insights Into the Emerging Drugs, Latest FDA Approvals, Clinical Trials, Therapies, Key Companies"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1713768890.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Bipolar Disorder Pipeline Assessment, 2024 | In-depth Insights Into the Emerging Drugs, Latest FDA Approvals, Clinical Trials, Therapies, Key Companies\" src=\"https:\/\/www.abnewswire.com\/uploads\/1713768890.jpeg\" alt=\"Bipolar Disorder Pipeline Assessment, 2024 | In-depth Insights Into the Emerging Drugs, Latest FDA Approvals, Clinical Trials, Therapies, Key Companies\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Bipolar Disorder Pipeline Insights<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cBipolar Disorder &#8211; Pipeline Insight, 2024,\u201d report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Bipolar Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">As per DelveInsight&rsquo;s assessment, globally, about 22+ key pharma and biotech companies are working on 22+ pipeline drugs in the Bipolar Disorder (Manic Depression) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/p>\n<p style=\"text-align: justify;\"><strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Bipolar Disorder (Manic Depression) Pipeline Insight, 2024<\/a>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Bipolar Disorder Market.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The Bipolar Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bipolar-disorder-manic-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Bipolar Disorder (Manic Depression) Pipeline Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights into the emerging therapies for the treatment of Bipolar Disorder and the aggregate therapies developed by major pharma companies.<\/li>\n<li>It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.<\/li>\n<li>It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Bipolar Disorder market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s Report covers around 22+ products under different phases of clinical development like &ndash;&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I)&nbsp;<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">The Bipolar Disorder Pipeline report provides the therapeutic assessment of emerging drugs by the Route of Administration. Products have been categorized under various ROAs, such as:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Inhalation<\/li>\n<li>Inhalation\/Intravenous\/Oral<\/li>\n<li>Intranasal<\/li>\n<li>Intravenous<\/li>\n<li>Intravenous\/ Subcutaneous<\/li>\n<li>Oral<\/li>\n<li>Oral\/intranasal\/subcutaneous<\/li>\n<li>Parenteral<\/li>\n<li>Subcutaneous<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">The Report Covers the Pipeline Products Under various Molecule types, such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Antibody<\/li>\n<li>Antisense oligonucleotides<\/li>\n<li>Immunotherapy<\/li>\n<li>Monoclonal antibody<\/li>\n<li>Peptides<\/li>\n<li>Protein<\/li>\n<li>Recombinant protein<\/li>\n<li>Small molecule<\/li>\n<li>Stem Cell<\/li>\n<li>Vaccine<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Learn How the Ongoing Clinical &amp; Commercial Activities will Affect the Bipolar Disorder Therapeutic Segment @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bipolar-disorder-manic-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/sample-request\/bipolar-disorder-manic-depression-pipeline-insight<\/a><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Bipolar Disorder (Manic Depression) Therapeutics Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 22+ key companies which are developing therapies for Bipolar Disorder. Vanda Pharmaceuticals is leading the therapeutics market with its Bipolar Disorder drug candidates in the most advanced stage of clinical development among all the key players.<\/p>\n<p style=\"text-align: justify;\"><strong>The Leading Companies in the Bipolar Disorder (Manic Depression) Therapeutics Market Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Vanda Pharmaceuticals<\/li>\n<li>Reviva Pharmaceuticals<\/li>\n<li>SK BIOPHARMACEUTICALS<\/li>\n<li>Pear Therapeutics<\/li>\n<li>Arvelle Therapeutics<\/li>\n<li>Janssen Research &amp; Development<\/li>\n<li>Sunovion Pharmaceuticals<\/li>\n<li>Lyndra Therapeutics<\/li>\n<li>ILTOO Pharma<\/li>\n<li>COMPASS Pathways<\/li>\n<li>NRx Pharmaceuticals<\/li>\n<li>Carlsson Research AB<\/li>\n<li>Sunovion<\/li>\n<li>SAGE Therapeutics<\/li>\n<li>Alzamend Neuro<\/li>\n<li>OWP Pharmaceuticals<\/li>\n<li>Entheogenix Biosciences<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And Many Others<\/p>\n<p style=\"text-align: justify;\"><strong>Bipolar Disorder (Manic Depression) Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Iloperidone: Vanda Pharmaceuticals<\/li>\n<li>RP5063: Reviva Pharmaceuticals<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And Many More<\/p>\n<p style=\"text-align: justify;\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bipolar-disorder-manic-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/sample-request\/bipolar-disorder-manic-depression-pipeline-insight&nbsp;<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Bipolar Disorder Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Bipolar Disorder &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Bipolar Disorder Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Bipolar Disorder Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Bipolar Disorder Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Bipolar Disorder Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Bipolar Disorder Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Key Companies in the Bipolar Disorder Market<\/p>\n<p style=\"text-align: justify;\">15. Key Products in the Bipolar Disorder Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Bipolar Disorder Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Bipolar Disorder Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Bipolar Disorder Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=bipolar-disorder-pipeline-assessment-2024-indepth-insights-into-the-emerging-drugs-latest-fda-approvals-clinical-trials-therapies-key-companies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=bipolar-disorder-pipeline-assessment-2024-indepth-insights-into-the-emerging-drugs-latest-fda-approvals-clinical-trials-therapies-key-companies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bipolar Disorder Pipeline Insights DelveInsight\u2019s, \u201cBipolar Disorder &#8211; Pipeline Insight, 2024,\u201d report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Bipolar Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/bipolar-disorder-pipeline-assessment-2024-indepth-insights-into-the-emerging-drugs-latest-fda-approvals-clinical-trials-therapies-key-companies_695953.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-695953","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/695953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=695953"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/695953\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=695953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=695953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=695953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}